Viral Protein Patents (Class 536/23.72)
  • Publication number: 20130310443
    Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.
    Type: Application
    Filed: March 15, 2013
    Publication date: November 21, 2013
    Inventors: ARUN SRIVASTAVA, GEORGE VLADIMIROVICH ASLANIDI, KIM M. VAN VLIET, MAVIS AGBANDJE-MCKENNA
  • Patent number: 8586055
    Abstract: This invention provides DNA vaccines for the treatment of patients undergoing anti-retroviral therapy. The vaccines are surprisingly effective at controlling viremia.
    Type: Grant
    Filed: January 14, 2008
    Date of Patent: November 19, 2013
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Barbara Felber, George N. Pavlakis
  • Patent number: 8586826
    Abstract: It is intended to provide a polynucleotide comprising a viral base sequence, the viral base sequence containing: a first base sequence encoding a viral replication protein, and a second base sequence encoding a viral movement protein, the second base sequence being located downstream of the first base sequence and having a linking site for linking with an exogenous base sequence encoding a polypeptide to be expressed, the linking site being located downstream of the second base sequence, the second base sequence being obtained by modifying with a base sequence in a native sequence derived from a virus by insertion, substitution, or addition. By using this, a vector containing a viral base sequence is constructed, and a protein is efficiently produced without worsening growth of a host cell containing the vector.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: November 19, 2013
    Assignee: Japan Science and Technology Agency
    Inventors: Masashi Mori, Koji Dohi
  • Publication number: 20130302364
    Abstract: The invention relates to peptides comprising part or all of a conserved element within a Center-of-Tree (COT) sequence derived from a family of polypeptides encoded by naturally occurring variants of HIV. The invention also relates to immunogenic compositions and vaccines comprising said peptides. The invention also relates to methods for the identification of HIV controller patients based on the detection of the T cells of the patient to mount a cytotoxic T cell response against said peptides and to methods for the identification of immunogenic peptides within a family of variant polypeptides.
    Type: Application
    Filed: November 10, 2011
    Publication date: November 14, 2013
    Applicants: LABORATORIOS DEL DR. ESTEVE, S.A., UNIVERSITY OF WASHINGTON, INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS, FUNDACIÓ PRIVADA INSTITUT DE RECERCA DE LA SIDA - CAIXA
    Inventors: Beatriz Mothe Pujadas, Christian Brander, James I. Mullins
  • Patent number: 8580276
    Abstract: A vaccine comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified H5 (mH5) promoter operably linked to a DNA sequence encoding a heterologous foreign protein antigen, wherein the expression of said DNA sequence is under the control of the mH5 promoter; b) generating rMVA virus by transfecting one or more plasmid vectors obtained from step a) into wild type MVA virus; c) identifying rMVA virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rMVA virus strain identified by step d); and f) purifying the rMVA viruses from step e) to form the vaccine.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: November 12, 2013
    Assignee: City of Hope
    Inventors: Don Diamond, Zhongde Wang
  • Publication number: 20130295134
    Abstract: This invention relates to bicistronic flavivirus vectors, methods of using such vectors in the prevention and treatment of disease, and methods of making such vectors.
    Type: Application
    Filed: July 15, 2013
    Publication date: November 7, 2013
    Inventors: Simon DELAGRAVE, Nathan Brown, Harold Kleanthous, Farshad Guirakhoo, Alexander A. Rumyantsev
  • Publication number: 20130296541
    Abstract: The invention relates to a cDNA molecule which encodes the nucleotide sequence of the full length antigenomic (+)RNA strand of a measles virus (MV) originating from an approved vaccine strain. It also contains the preparation of immunogenic compositions using said cDNA.
    Type: Application
    Filed: July 24, 2008
    Publication date: November 7, 2013
    Inventors: Frederic Tangy, Chantal Combredet, Valerie Labrousse-Najburg, Michel Brahic
  • Publication number: 20130296532
    Abstract: The present invention relates nucleic acid constructs for the production of recombinant parvoviral (e.g. adeno-associated viral) vectors in insect cells, to insect cells comprising such constructs and to methods wherein the cells are used to produce recombinant parvoviral virions. The insect cells preferably comprise a first nucleotide sequence encoding the parvoviral rep proteins whereby the initiation codon for translation of the parvoviral Rep78 protein is a suboptimal initiation codon that effects partial exon skipping upon expression in insect cells. The insect cell further comprises a second nucleotide sequence comprising at least one parvoviral (AAV) inverted terminal repeat (ITR) nucleotide sequence and a third nucleotide sequence comprising a sequences coding for the parvoviral capsid proteins.
    Type: Application
    Filed: July 18, 2013
    Publication date: November 7, 2013
    Inventors: Wilhelmus Theodorus Johannes Maria Christiaan HERMENS, Saskia Jacoba Petronella HAAST, Dennis Johan BIESMANS, Andrew Christian BAKKER
  • Publication number: 20130295614
    Abstract: The present disclosure relates to recombinant adeno-associated virus (AAV) vector serotype, wherein the capsid protein of AAV serotypes is mutated at single or multiple sites. The disclosure further relates to an improved transduction efficiency of these mutant AAV serotypes. The AAV serotypes disclosed are AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10. The instant disclosure relates to nucleotide sequences, recombinant vector, methods and kit thereof.
    Type: Application
    Filed: May 2, 2013
    Publication date: November 7, 2013
    Inventors: Sangeetha Hareendran, Nishanth Gabriel, Dwaipayan Sen, Rupali Gadkar, Sudha Govindarajan, Narayana Swamy Srinivasan, Arun Srivastava, Alok Srivastava, Giridhara Rao Jayandharan, Ruchita Selot, Balaji Balakrishnan, Akshaya Krishnagopal
  • Patent number: 8568734
    Abstract: Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: October 29, 2013
    Assignee: Novartis Vaccines and Diagnostics Inc.
    Inventors: Vega Masignani, Maria Scarselli, Barbara Capecchi, Victoria Sharma, Susan W Barnett, Indresh K. Srivastava, Rino Rappuoli
  • Patent number: 8569472
    Abstract: The present inventors developed hepatitis C virus 6a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 6a reference strain HK6a. Sequence analysis of recovered 6a/2a recombinants from 2 transfection experiments and subsequent reverse genetic studies revealed adaptive mutations in E1 and E2. Conclusion: The developed 6a/2a viruses provide a robust in vitro tool for research in HCV genotype 6, including vaccine studies and functional analysis.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: October 29, 2013
    Assignee: Hvidovre Hospital
    Inventors: Judith M. Gottwein, Troels Kasper Hoyer Scheel, Tanja Bertelsen Jensen, Jens Bukh
  • Patent number: 8569579
    Abstract: The invention provides Bean pod mottle virus (BPMV) vectors useful for expression of heterologous proteins in plants such as soybean. The BPMV vectors are also useful for virus-induced gene silencing. The vectors of the invention include modifications of BPMV RNA1 sequences so that infection with the vectors produces only moderate symptoms. The vectors also comprise novel RNA2 vectors which specifically provide for non-translated VIGS constructs and further which do not require in frame insertion of heterologous sequences to be expressed.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: October 29, 2013
    Assignee: Iowa State University Research Foundation, Inc.
    Inventors: John H. Hill, Chunquan Zhang, Steve Whitham
  • Patent number: 8569473
    Abstract: The application relates to a pestivirus, designated PMC virus, that is associated with porcine myocarditis syndrome, and the gene and protein sequences derived therefrom. The application further relates to detection methods, vaccine therapeutics, and diagnostic methods using the PMC virus or gene/protein sequences derived therefrom.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: October 29, 2013
    Assignee: Intervet International B.V.
    Inventors: Melinda Jane Frost, Peter Daniel Kirkland, Deborah Susan Finlaison
  • Patent number: 8563706
    Abstract: The present inventors developed hepatitis C virus 1a/2a and 1b/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and NS2 were replaced by the corresponding genes of the genotype Ia reference strain H77C or TN or the corresponding genes of the genotype Ib reference strain J4. Sequence analysis of recovered 1a/2a and 1b/2a recombinants from 2 serial passages and subsequent reverse genetic studies revealed adaptive mutations in e.g. p7, NS2 and/or NS3. In addition, the inventors demonstrate the possibility of using adaptive mutations identified for one HCV isolate in generating efficient cell culture systems for other isolates by transfer of mutations across isolates, subtypes or major genotypes. Furthermore neutralization studies showed that viruses of e.g. genotype 1 were efficiently neutralized by genotype Ia, 4a and 5a serum, an effect that could be utilized e.g. in vaccine development and immunological prophylaxis.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: October 22, 2013
    Assignee: Hvidovre Hospital
    Inventors: Troels Kasper Hoyer Scheel, Judith M. Gottwein, Jannick Prento, Tanja Bertelsen Jensen, Jens Bukh
  • Publication number: 20130273107
    Abstract: This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 17, 2013
    Inventors: ADRIAN VILALTA, MICHAL MARGALITH, LICHUN DONG, DAVID M. KOELLE
  • Publication number: 20130273647
    Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.
    Type: Application
    Filed: September 19, 2011
    Publication date: October 17, 2013
    Applicants: BIONTECH AG, TRON- Translationale Onkologie an der Universi- ttttatsmedzin der Johannes Gutenberg- UNiversitat, Universitatsmedizin der Johannes Gutterberg- Universital MAinz
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
  • Publication number: 20130273108
    Abstract: This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 17, 2013
    Inventors: ADRIAN VILALTA, MICHAL MARGALITH, LICHUN DONG, DAVID M. KOELLE
  • Publication number: 20130273088
    Abstract: The present invention relates to diagnosis, prevention and treatment of Herpes simplex viruses and infection. In particular embodiments the present invention relates to methods and compositions for the prophylactic or therapeutic immunization against of infections of HSV. The present invention also relates to methods and compositions for diagnosis of the presence of and level of immunity to HSV. The invention also relates to peptide epitopes of HSV, in particular peptide epitopes of HSV2 glycoprotein D, to compositions thereof and to the use of such epitopes and compositions in methods for diagnosis, prevention and treatment of HSV.
    Type: Application
    Filed: July 7, 2008
    Publication date: October 17, 2013
    Inventors: Anthony Lawrence Cunningham, Min Kim
  • Patent number: 8557971
    Abstract: The invention relates to chimeric polytropic viral envelope polypeptides and uses thereof, as well as to polynucleotides encoding said chimeric polypeptides and constructs comprising said polypeptides and/or polynucleotides. The invention also relates to chimeric retroviral envelope polypeptides, polynucleotides and vectors encoding said chimeric retroviral envelope polypeptides, virus particles and cells harboring said chimeric envelope polypeptides. Said chimeric polypeptide comprise an envelope polypeptide, or fragment thereof, and a polypeptide sequence of a receptor binding region, ligand or polypeptide sequence of a ligand binding region, and optionally a linker sequence. The invention include methods of targeting receptors, methods of treatment and methods for delivery of agents using said chimeric retroviral envelope polypeptides. The invention is applicable for directed targeting and controlled fusion of virus particles with other cellular membranes.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: October 15, 2013
    Assignee: Aarhus Universitet
    Inventors: Finn Skou Pedersen, Shervin Bahrami, Mogens Ryttergaard Duch, Lars Østergaard, Martin Tolstrup
  • Publication number: 20130266600
    Abstract: The present invention provides recombinant respiratory syncytial viruses that have an attenuated phenotype and that comprise one or more mutations in the viral P, M2-1 and/or M2-2 proteins, as well as live attenuated vaccines comprising such viruses and nucleic acids encoding such viruses. Recombinant RSV P, M2-1 and M2-2 proteins are described. Methods of producing attenuated recombinant RSV, and methods of quantitating neutralizing antibodies that utilize recombinant viruses of family Paramyxoviridae, are also provided.
    Type: Application
    Filed: January 16, 2013
    Publication date: October 10, 2013
    Inventors: Hong Jin, Robert Brazas, Bin Lu
  • Patent number: 8551495
    Abstract: The present invention pertains to the field of immunology and genetic engineering. In particular, the present invention relates to the construction, preparation and use of a recombinant vaccine against foot-and-mouth disease virus. The vaccine comprises a tandem repeat of an antigenic epitope of FMDV VP1 protein, the constant region of the immunoglobulin heavy chain or a functional fragment thereof, and the FMDV 3D protein or an immunogenic fragment thereof. The vaccine can induce protective immune response against FMDV in an animal.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: October 8, 2013
    Assignee: Pharos Vaccine Inc.
    Inventor: Yu Wang
  • Publication number: 20130259869
    Abstract: The present invention relates to rearranged molecules of (a) a specific TT virus sequence and (b) a nucleotide sequence encoding a polypeptide showing homology to mammalian proteins associated with cancer and autoimmune diseases that are capable of replicating autonomously for use in diagnosis, prevention and treatment of diseases like cancer and autoimmunity.
    Type: Application
    Filed: December 19, 2012
    Publication date: October 3, 2013
    Applicant: Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechtes
    Inventor: Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechtes
  • Publication number: 20130251719
    Abstract: The present invention refers to a novel circovirus as causative agent of bone marrow aplasia with haemorrhagic disease in cattle. The present invention provides novel nucleic acid and protein sequences for diagnostic and therapeutic uses.
    Type: Application
    Filed: October 22, 2010
    Publication date: September 26, 2013
    Applicants: Tiergesundheitsdienst Bayern E.V., Universitat Leipzig
    Inventors: Hermann Muller, Mohammad Yahya Halami, Jens Bottcher, Eva Kappe, Benjamin Schade
  • Publication number: 20130251747
    Abstract: The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising said recombinant EHV-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 26, 2013
    Applicants: FREIE UNIVERSITÄT BERLIN, MERIAL LIMITED
    Inventors: Jean Christophe Audonnet, Jules Maarten Minke, Nikolaus Osterrieder, Guanggang Ma
  • Publication number: 20130230548
    Abstract: Provided is a truncated L1 protein of Human Papillomavirus (HPV) Type 52 which, compared to a wild type HPV52 L1 protein, is truncated by 27-42 amino acids at the N-terminal. Also provided are a coding sequence of the truncated HPV52 L1 protein, a virus-like particle (VLP) comprising the protein, and a method of preparing the protein and the VLP using an E. coli expression system. The truncated HPV52 L1 protein and an assembled VLP can be used to prevent an HPV52 infection and a disease caused by HPV52 infection, such as cervical cancer.
    Type: Application
    Filed: July 1, 2011
    Publication date: September 5, 2013
    Applicant: XIAMEN UNIVERSITY
    Inventors: Shaowei Li, Xiaobing Mo, Minxi Wei, Huirong Pan, Jun Zhang, Ningshao Xia
  • Publication number: 20130230529
    Abstract: Described herein are isolated paramyxovirus, a morbillivirus (FmoPV), isolated nucleic acids encoding the genome of FmoPV, isolated amino acid sequences of FmoPV proteins, antibodies to FmoPV and its proteins, and uses thereof. In certain embodiments, the modified FmoPV is a feline morbillivirus. Also described herein is a recombinant FmoPV comprising a modified FmoPV gene or gene segments and the use of such a virus. The recombinant FmoPV may be used in the prevention and/or treatment of diseases related to FmoPV or as a delivery vector. Also described herein is a diagnostic assay for the FmoPV. In certain embodiments, the FmoPV causes kidney disease. In certain embodiments, the kidney disease is in felines. In certain embodiments, the kidney disease is tubulointerstitial nephritis (“TIN”). Also described herein is a quantitative assay for the detection of the FmoPV, natural or artificial variants, analogs, or derivatives thereof.
    Type: Application
    Filed: January 22, 2013
    Publication date: September 5, 2013
    Applicant: The University of Hong Kong
    Inventors: Kwok-Yung Yuen, Patrick Chiu-Yat Woo, Susanna Kar-Pui Lau
  • Patent number: 8524446
    Abstract: A method for detecting and isolating AAV sequences in a sample of DNA obtained from tissue or cells is provided, which sample contains DNA and proviral AAV. The method involves subjecting the sample containing DNA to amplification via polymerase chain reaction (PCR) using a first set of primers which specifically amplify a first AAV region. The first AAV region is characterized by having at least 250 nucleotides of AAV capsid nucleic acid sequence, a variable sequence flanked by a sequence of at least 18 nucleotides at the 5? end of the first AAV region and a sequence of at least 18 nucleotides at the 3? end of the first AAV region. Each of the 5? and 3? at least 18 nucleotides is the same over at least 9 consecutive nucleotides relative to corresponding sequences in an alignment of at least two AAV serotypes. Each of the sets of primers consist of a 5? primer and a 3? primer. The method is further useful for identifying AAV sequences in the sample by the presence of amplified proviral AAV sequences.
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: September 3, 2013
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M Wilson, Mauricio R. Alvira
  • Patent number: 8524248
    Abstract: The present invention provides isolated or substantially purified polypeptides, nucleic acids, and virus-like particles (VLPs) derived from a Merkel cell carcinoma virus (MCV), which is a newly-discovered virus. The invention further provides monoclonal antibody molecules that bind to MCV polypeptides. The invention further provides diagnostic, prophylactic, and therapeutic methods relating to the identification, prevention, and treatment of MCV-related diseases.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: September 3, 2013
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Patrick S. Moore, Yuan Chang, Huichen Feng, Christopher Brian Buck, Diana V. Pastrana
  • Publication number: 20130225479
    Abstract: The present invention provides methods and compositions for treating inflammation and inflammatory disorders in a subject, by administering an effective amount of KSHV-Orf63 and/or active peptides and/or fragments thereof.
    Type: Application
    Filed: August 26, 2011
    Publication date: August 29, 2013
    Applicant: The University of North Carolina at Chapel Hill
    Inventors: Blossom Damania, Jenny P.-Y. Ting, Sean Gregory
  • Publication number: 20130224236
    Abstract: The invention provides HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Application
    Filed: November 3, 2011
    Publication date: August 29, 2013
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: David M. Koelle, Lichen Jing
  • Patent number: 8519113
    Abstract: This invention comprises a combined transgene/virus vector system for the expression of heterologous proteins in plants. While exemplified with respect to the bipartite RNA plant virus, Cowpect mosaic virus (CPMV), other bipartite viral systems may be used to advantage according to the method, system and composition described in detail herein.
    Type: Grant
    Filed: May 22, 2006
    Date of Patent: August 27, 2013
    Assignee: Plant Bioscience Limited
    Inventors: George Lomonossoff, Li Liu, Carmen Canizares, Marc-Andre D'Aoust, Louis-Philippe Vezina
  • Publication number: 20130216567
    Abstract: The invention relates to a newly identified avian rotavirus D VP6 nucleotide sequence and uses thereof.
    Type: Application
    Filed: March 4, 2011
    Publication date: August 22, 2013
    Applicant: Novartis AG
    Inventor: Bernhard Roth
  • Publication number: 20130216613
    Abstract: The invention relates to a cytomegalovirus (CMV) gB polypeptide comprising at least a portion of a gB protein extracellular domain comprising a fusion loop 1 (FL1) domain and a fusion loop 2 (FL2) domain, wherein at least one of the FL1 and FL2 domains comprises at least one amino acid deletion or substitution.
    Type: Application
    Filed: October 14, 2011
    Publication date: August 22, 2013
    Inventors: Guy Jean Marie Fernand Pierre Baudoux, Normand Blais, Martine Marchand
  • Patent number: 8513397
    Abstract: Plant viral vectors have great potential in rapid production of proteins, but no simple. Here a geminivirus-based system for high-yield and rapid production of oligomeric protein complexes, including virus-like particle (VLP) vaccines and monoclonal antibodies (mAbs) is described. In particular, a single vector that contains two non-competing replicons for transient expression in Nicotiana benthamiana leaves is described. The correct assembly of these subunit proteins into functional oligomeric structures (VLPs or full-size mAb) is also described. This system advances plant transient expression technology by eliminating the need for non-competing viruses, and thus, enhances the realistic commercial application of this technology for producing multiple-subunit protein complexes.
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: August 20, 2013
    Assignee: The Arizona Board of Regents for and on behalf of Arizona State University
    Inventors: Hugh S. Mason, Zhong Huang, Qiang Chen, Charles J. Arntzen, Shuo Yuan, Brooke Hjelm
  • Publication number: 20130209395
    Abstract: Provided herein are nucleic acid sequences encoding hepatitis B virus (HBV) core proteins, surface antigen proteins, fragments and combinations thereof as well as genetic constructs/vectors and vaccines that express said protein sequences. These vaccines are able to induce an immune response peripherally and in the liver by recruiting both cellular and humoral agents. Also provided are methods for prophylactically and/or therapeutically immunizing individuals against HBV. The combination vaccine can also be used for particular design vaccines for particular levels of immune responses to HBV challenge.
    Type: Application
    Filed: September 19, 2012
    Publication date: August 15, 2013
    Inventors: David B. WEINER, Jian YAN, Nyamekye OBENG-ADJEI
  • Publication number: 20130210150
    Abstract: The present invention provides Sendai virus vectors in which genes that encode reprograming factors for inducing pluripotent stem cells are incorporated in a specific order, compositions comprising these vectors for gene delivery to be used in the induction of pluripotent stem cells, and uses thereof. Incorporation of the KLF gene, OCT gene, and SOX gene in a specific order into a single Sendai virus vector successfully and significantly increased the efficiency of pluripotent stem cell induction. Loading multiple reprogramming factors into a single vector can further increase the induction efficiency of pluripotent stem cells while reducing the number of necessary vectors.
    Type: Application
    Filed: August 30, 2011
    Publication date: August 15, 2013
    Applicant: DNAVEC Corporation
    Inventors: Hiroshi Ban, Yasuji Ueda, Noemi Fusaki, Koichi Saeki, Mamoru Hasegawa
  • Publication number: 20130209402
    Abstract: The present invention relates to human papillomavirus E7 antigen compounds and compositions for treating human papillomavirus infection and associated conditions. The invention provides, in part, polypeptide and nucleic acid molecules including sequences substantially identical to the sequences of two or more human papillomavirus (HPV) E7 antigens, where the E7 antigens are selected from at least two different HPV strains, and methods of using the same.
    Type: Application
    Filed: July 15, 2011
    Publication date: August 15, 2013
    Applicant: BRITISH COLUMBIA CANCER AGENCY BRANCH
    Inventors: John R. Webb, Darin Arne Wick
  • Publication number: 20130209499
    Abstract: Provided herein are polypeptides comprising portions of the influenza virus hemagglutinin, compositions comprising such polypeptides that can be used as immunogens in vaccines and methods of their use to generate an immune response against multiple influenza subtypes in a subject.
    Type: Application
    Filed: February 18, 2011
    Publication date: August 15, 2013
    Applicant: Mount Sinai School of Medicine
    Inventors: Adolfo Garcia-Sastre, Peter Palese, Gens S. Tan, Taia T. Wang
  • Patent number: 8507267
    Abstract: The present invention provides an adeno-associated virus 4 (AAV4) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV4 vectors and particles.
    Type: Grant
    Filed: March 8, 2010
    Date of Patent: August 13, 2013
    Assignee: U.S. Dept. of Health and Human Services, National Institutes of Health
    Inventors: John A. Chiorini, Robert M. Kotin, Nancy Safer
  • Publication number: 20130202640
    Abstract: This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 8, 2013
    Applicants: Vical Incorporated, THE UNIVERSITY OF WASHINGTION
    Inventors: THE UNIVERSITY OF WASHINGTION, Vical Incorporated
  • Publication number: 20130202638
    Abstract: The present invention is related to a beta-herpesvirus, wherein the beta-herpesvirus is spread-deficient.
    Type: Application
    Filed: May 5, 2011
    Publication date: August 8, 2013
    Inventors: Christian Thirion, Ulrich Koszinowski, Christian A. Mohr, Zsolt Ruzsics
  • Patent number: 8501450
    Abstract: The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: August 6, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Chao Lin, Tara Kieffer, Christoph Sarrazin, Ann Kwong
  • Publication number: 20130195915
    Abstract: A novel influenza C virus with only low homology to any influenza C virus previously characterized. Challenge studies show that the virus can infect pigs and be transmitted between pigs. Additionally, influenza C is commonly thought of as a human pathogen and serological studies have been performed, looking at the incidence of antibodies against this virus in both pigs and humans. Approximately 10% of pigs and 30% of humans have antibodies to this virus. Additional experimental data show that the virus can infect and transmit in ferrets (a surrogate for human infection studies). In a third aspect, the present invention is the partial genome of this novel influenza C virus. In another aspect, the present invention is a method of detection in animals of this novel influenza C virus.
    Type: Application
    Filed: January 27, 2012
    Publication date: August 1, 2013
    Applicant: Newport Laboratories
    Inventors: Randy R. Simonson, Benjamin M. Hause, Emily A. Collin
  • Publication number: 20130195904
    Abstract: We identified regions of the HIV-1 proteome with high conservation, and low variant incidence. Such highly conserved sequences have direct relevance to the development of new-generation vaccines and diagnostic applications. The immune relevance of these sequences was assessed by their correlation to previously reported human T-cell epitopes and to recently identified human HIV-1 T-cell epitopes (identified using HLA transgenic mice). We identified (a) sequences specific to HIV-1 with no shared identity to other viruses and organisms, and (b) sequences that are specific to primate lentivirus group, with multiclade HIV-1 conservation.
    Type: Application
    Filed: January 4, 2011
    Publication date: August 1, 2013
    Applicants: NATIONAL UNIVERSITY OF SINGAPORE, THE JOHNS HOPKINS UNIVERSITY
    Inventors: J. Thomas August, Gregory George Simon, Tin Wee Tan, Asif Mohammad Khan, Hu Yongli
  • Publication number: 20130189265
    Abstract: Described are parvovirus variants derived, e.g., from H-1PV, showing higher anti-tumor potential compared to the wild type parvovirus, wherein said variant is characterized by (a) an amino acid substitution, alteration or addition, preferably substitution at position Lys96 of NS-2 and/or position Leu103 of NS-2 (together with a amino acid substituion at position Tyr595 of NS-1 in the latter case), or (b) an in-frame deletion in the parvovirus genome, preferably a deletion resulting in a large amino acid deletion in both the central part (aa 96-133) of NS-2 and the C-terminal part (aa 587-624) of NS-1. The present invention also relates to the use of said parvovirus variants for cancer therapy.
    Type: Application
    Filed: December 13, 2012
    Publication date: July 25, 2013
    Applicant: DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventor: DEUTSCHES KREBSFORSCHUNGSZENTRUM
  • Publication number: 20130189779
    Abstract: Disclosed are an HCV gene having higher replication efficiency and higher reinfection efficiency than the known HCV gene of genotype 1b, an RNA replicon having this gene, a cell infected with this RNA replicon, which cell allows replication of HCV, and an HCV particle. The hepatitis C virus gene encodes an amino acid sequence wherein the 979th amino acid is threonine; the 1804th amino acid is leucine; and the 1966th amino acid is lysine. An HCV gene which can propagate in vitro and has higher replication efficiency and higher reinfection efficiency than the known HCV gene of genotype 1b was provided.
    Type: Application
    Filed: October 7, 2011
    Publication date: July 25, 2013
    Applicant: ADVANCED LIFE SCIENCE INSTITUTE, INC.
    Inventors: Kenichi Mori, Noboru Maki, Hiromi Fukai
  • Publication number: 20130190231
    Abstract: The present invention relates to a composition for preventing, alleviating or treating obesity comprising a partial fragment of HIV-1 (Human Immunodeficiency Virus-1) Tat (Trans activator of transcription) protein. The peptides of the present invention induce anorexia and increase lipolysis, ?-oxidation of free fatty acids, thermogenesis, and total energy expenditure, therefore may be effectively used for preventing or treating diseases related to metabolic imbalance such as obesity.
    Type: Application
    Filed: December 24, 2009
    Publication date: July 25, 2013
    Inventors: Man-Wook Hur, Jae-Eun Kang, Min-Seon Kim, Kyung-Sup Kim
  • Publication number: 20130189303
    Abstract: Recombinant, chimeric porcine influenza viruses are disclosed that include hemagglutinin segments from more than one influenza virus subtype. Also described are methods of producing the recombinant influenza viruses, immunogenic compositions comprising the recombinant influenza viruses, methods of stimulating an immune response against influenza virus, and methods of treating and preventing influenza virus infection.
    Type: Application
    Filed: July 27, 2012
    Publication date: July 25, 2013
    Inventors: Yan Zhou, Aleksandar Masic
  • Publication number: 20130189294
    Abstract: Described is a method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection that have been identified via the methods of the invention. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Application
    Filed: March 15, 2013
    Publication date: July 25, 2013
    Applicant: UNIVERSITY OF WASHINGTON
    Inventor: University of Washington
  • Patent number: 8492532
    Abstract: A nucleic acid molecule containing nucleotide sequences that encode the capsid protein, pre-membrane protein and non-structural protein of Japanese encephalitis virus, and a nucleotide sequence that encodes the envelop protein of a second flavivirus, wherein the nucleotide sequence(s) that encode(s) the pre-membrane protein and/or non-structural protein of Japanese encephalitis virus contain(s) nucleotide mutations that produce one or more amino acid mutations that attenuate the virus.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: July 23, 2013
    Assignee: The Research Foundation for Microbial Diseases of Osaka University
    Inventors: Kouichi Morita, Takeshi Nabeshima, Shinichi Miyake, Toshiyuki Onishi, Isao Fuke, Toyokazu Ishikawa, Hideo Goda, Masahide Ishibashi, Michiaki Takahashi